30 closest matches · ranked by relevance
Beta Haemolytic Streptococcal Infection
Primary: The Time to First Vaginal Swab That is Type III GBS Culture Positive, With All Previous Cultures Negative for Type III GBS, Not Just the Immediately Preceding Culture…
Group B Streptococcal Infections
Primary: Safety and Tolerability of the GBS-NN/NN2 Vaccine for 4 Weeks After Each Dose of Vaccine — 23; 21; 5; 10 Participants
Guillain-Barre Syndrome
Primary: Time to First Reaching a Hughes Functional Grade (FG) Score <=1 — 112.0; 168.0 Days — p=0.8938
Guillain-Barré Syndrome (GBS)
Primary: Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 Grade — 6.0 days
Infection by Streptococcus Group B
Primary: Part A Number of Participants With Treatment Emergent Adverse Events — 6; 5; 5; 6 participants
Gaucher Disease, Type 1
Primary: Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group. — 2.429 g/dL — p=<0.0001
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…
Dystrophic Epidermolysis Bullosa
Primary: Percent Change of Active Blisters and in Total Blister/Erosion Counts — -29.6 percent change — p=0.82
Gaucher Disease, Type 1
Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Gaucher Disease
Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL
GBS Disease · Streptococcus Agalactiae
Primary: Concentration of Serotype Ia GBS IgG Levels in Infant Serum at Delivery and at Days 42 and 90 of Age — 6.98; 0.24; 6.18; 0.39 µg/mL
Group B Strep Infection
Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants
Bacterial Infection Due to Streptococcus, Group B · Streptococcus Agalactiae
Primary: Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61 — 100; 100; 100; 100 Percentage of subjects
Streptococcal Infections · Gram-Positive Bacterial Infections · Bacterial Infections
Primary: Geometric Mean Concentrations (GMCs) of Antibodies in Maternal Subjects and Infants at Delivery/Birth — 2.07; 2.31; 3.98; 1.01 μg/mL
Gaucher Disease
Primary: Participants Who Experienced at Least One Adverse Event — 34 participants
Gaucher Disease
Primary: Change From Baseline in Spleen Volume Measured by MRI. — -26.91; -38.01 percentage of change — p=<0.0001
Group B Streptococcus Infection
Primary: Treatment Emergent Adverse Events — 10; 7; 10; 4 Participants
Group B Streptococcal Infections
Primary: Percentage of Participants Reporting Prompted Local Reactions Within 14 Days Following Booster Dose (Redness, Swelling, and Pain at the Injection Site) — 68.4; 42.7…
Infection · Pregnancy
Primary: Count of Participants With Positive Group B Streptococcus Rectovaginal Colonization Status at 35- 37 Weeks' Gestational Age — 20; 23 Participants — p=0.87
Epilepsy
Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr
Anti-Glomerular Basement Membrane Antibody Disease
Primary: Number of Patients With Independent Renal Function at 6 Months — 5; 5; 10 Participants
Group B Streptococcal Infection
Primary: Concentrations of Immunoglobulin (Ig) G Antibodies Specific to the AlpN Proteins in μg/mL in Cord Blood From Each Baby — 11.12; 5.52; 7.95; 3.51 μg/mL
Multiple Sclerosis
Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…
Group B Streptococcal Infection
Primary: Number of GBS-Positive Pregnant Women Who Became GBS-Negative at Childbirth — 21; 9 Participants
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Recumbent Height/Length of Participants in Centimeters (cm) — 80.4; 93.8; 67.7; 91.1 cm
Pompe Disease
Primary: Safety Assessments of the rAAV1-CMV-GAA (Study Agent), Changes Post Study Agent Administration. — 40,031; 29,638; 5,509,882; 1,907,161 mU/mL